A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...
Nivolumab plus ipilimumab prolonged PFS when compared to nivolumab alone in patients with MSI-H/dMMR unresectable or ...
Medpage Today on MSN1d
Combination Slows Metastatic CRC Progression Better Than Single ImmunotherapyMedian duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...
Researchers compare nivolumab as monotherapy or in combination with chemotherapy vs conventional treatment on overall survival and progression-free survival in patients with advanced unresectable ...
The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...
(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...
Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...
The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...
Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...
Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...
Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback